Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3

Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3

Hepatocellular carcinoma (HCC) is highly refractory to current therapeutics used in the clinic. DX-2647, a recombinant human antibody, potently neutralizes the action of insulin-like growth factor-II (IGF-II), a ligand for three cell-surface receptors (IGF-IR, insulin receptor A and B isoforms, and...

Full description

Bibliographic Details
Main Authors: Sameer A. Greenall, Jacqueline Donoghue, Terrance G. Johns, Timothy E. Adams
Format: Article
Language:English
Published: Elsevier 2018-08-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523318301165

Similar Items

Similar Items